EpiCast Report: Gram-Negative Bacterial Urinary Tract Infection – Epidemiology Forecast to 2022
Table Of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.2.1 Women are more likely than men to experience UTI at all ages 11
3.2.2 The risk of developing UTI increases 3%-6% per day of catheterization 11
3.2.3 Older age is a major risk factor for UTI 12
3.2.4 Sexual intercourse can increase the relative odds of UTI in women by a factor as high as 60 13
3.2.5 Diabetic individuals have an increased incidence of UTI and increased associated complications 13
3.3 Forecast Methodology 14
3.3.1 Sources Used 15
3.3.2 Forecast Assumptions and Methods 19
3.4 Epidemiological Forecast for UTI (2012-2022) 24
3.4.1 US 24
3.4.2 5EU 29
3.4.3 Japan 36
3.5 Discussion 41
3.5.1 Conclusions on Epidemiological Trends 41
3.5.2 Limitations of the Analysis 42
3.5.3 Strengths of the Analysis 43
4 Appendix 44
4.1 Bibliography 44
4.2 About the Authors 49
4.2.1 Epidemiologists 49
4.2.2 Reviewers 49
4.2.3 Franka des Vignes, PhD, Global Director of Epidemiology and Health Policy 51
4.2.4 Bonnie Bain, PhD, Global Head of Healthcare 51
4.3 About GlobalData 52
4.4 About EpiCast 52
4.5 Disclaimer 53
List of Tables
Table 1: Risk Factors for Urinary Tract Infection 11
Table 2: Sources of Incidence Data Used in the Epidemiology Forecast 14
Table 3: US, Incident Cases of Gram-Negative UTI, N, by Site of Acquisition, Select Years, 2012-2022 25
Table 4: US, Incident Cases of Gram-Negative UTI, by Age and Site of Acquisition, N (Row %), 2012 26
Table 5: US, Incident Cases of Gram-Negative UTI, by Sex and Site of Acquisition, N (Row %), 2012 27
Table 6: US, Incident Cases of Gram-Negative UTI, by Pathogen and Site of Acquisition, N (Column %), 2012 28
Table 7: US, Incident Cases of Gram-Negative UTI, by Pathogen and Multidrug* and Carbapenem Resistance, N, Percentage of Pathogen-Specific Cases, 2012 29
Table 8: 5EU, Incident Cases of UTI, N, Select Years, 2012-2022 30
Table 9: 5EU, Incident Cases of UTI, by Age, N (Row %), 2012 31
Table 10: 5EU, Incident Cases of UTI, by Sex, N (Row %), 2012 32
Table 11: 5EU, Incident Cases of UTI, by Pathogen, N (Percentage of Total Country-Specific Cases Caused by Pathogen), 2012 33
Table 12: 5EU, Incident Cases of UTI, by Pathogen and Multidrug and Carbapenem Resistance, N, and Percentage of Pathogen-Specific Cases, 2012 35
Table 13: Japan, Incident Cases of UTI, N, Select Years, 2012-2022 36
Table 14: Japan, Incident Cases of UTI, by Age, N (Row %), 2012 37
Table 15: Japan, Incident Cases of UTI, by Sex, N (Row %), 2012 38
Table 16: Japan, Incident Cases of UTI, by Pathogen, N (Percentage of Total Country-Specific Cases Caused by Pathogen), 2012 39
Table 17: Japan, Incident Cases of UTI, by Pathogen and Antibiotic, Number of Antibiotic-Resistant Cases (N) and Percentage of Antibiotic-Resistant Pathogen-Specific Cases (%), 2012 40
List of Figures
Figure 1: US, Incident Cases of Gram-Negative UTI, N, by Site of Acquisition, Select Years, 2012-2022 25
Figure 2: US, Incident Cases of Gram-Negative UTI, by Age and Site of Acquisition, N, 2012 26
Figure 3: US, Incident Cases of Gram-Negative UTI, by Sex, N, 2012 27
Figure 4: US, Incident Cases of Gram-Negative UTI, by Pathogen and Site of Acquisition, N, 2012 28
Figure 5: 5EU, Incident Cases of UTI, N, Select Years, 2012-2022 30
Figure 6: 5EU, Incident Cases of UTI, by Age, N, 2012 31
Figure 7: 5EU, Incident Cases of UTI, by Sex, N, 2012 32
Figure 8: 5EU, Incident Cases of UTI, by Pathogen, N, 2012 34
Figure 9: Japan, Incident Cases of UTI, N, Select Years, 2012-2022 36
Figure 10: Japan, Incident Cases of UTI, by Age, N, 2012 37
Figure 11: Japan, Incident Cases of UTI, by Sex, N, 2012 38
Figure 12: Japan, Incident Cases of UTI, by Pathogen, N, 2012 39
Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 – New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options
Published: 29-Oct-2014 Price: US $4995 Onwards
GBI Research, a leading business intelligence provider, has released its latest research report: “Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options”, which provides in-depth insight into the indication. It provides estimates of market size for 2013 along with forecasts until 2020 for the eight major developed markets, which comprises the US, UK, France, Germany, Italy, Spain, Japan......
Cell Expansion Market by Product (Reagent, Media, Serum, Bioreactors, Centrifuge), Cell Type (human, animal), Application (Stem Cell Research, Regenerative Medicine, Clinical Diagnostics), End User (Hospital, Biotechnology, Cell Bank) – Forecast to 2019
Published: 29-Oct-2014 Price: US $4650 Onwards Pages: 224
The global cell expansion market is expected to reach $14.8 billion by 2019 from $6.0 billion in 2014, growing at a CAGR of 19.7% from 2014 to 2019. The global cell expansion market is categorized on the basis of product, cell type, application, end user, and geography. The human cell expansion segment is expected to register the highest growth rate in the cell expansion market, by cell type, during the forecast period. Its favorable growth is attributed to increasing focus on human stem cell re......
Aortic Stent Grafts – Current and Future Players
Published: 29-Oct-2014 Price: US $3500 Onwards Pages: 106
Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient’s native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Aortic aneurysms, as opposed to aneurysms found elsewhere in the body, are potentially very serious, as a burst aorta results in massive internal bleeding that can be fatal unless treated r......
Identifying and Commercializing First-in-Class Innovation in Non-Small-Cell Lung Carcinoma
Published: 29-Oct-2014 Price: US $6995 Onwards
Large Degree of Innovation in NSCLC Pipeline
The NSCLC pipeline currently has 389 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current market and the pipeline is evident. Where the market comprises primarily ineffective chemotherapies that target tubulin or DNA replication, the pipeline shows an incredibly diverse range of therapies targeting multiple signaling pathways and molecules integral to cancer development. Thi......
Global Biologic Therapeutics Market 2014-2018
Published: 29-Oct-2014 Price: US $3500 Onwards Pages: 185
Biologic therapeutics include virus, therapeutic serum, toxin, allergenic product, antitoxin, blood component or derivative, vaccine, blood, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), intended for the prevention, treatment, or cure of a disease or condition. These products differ from small molecules in terms of molecular weight, structure, synthesis, and immunogen......
Egypt Pharmaceuticals and Healthcare Report Q4 2014
Published: 29-Oct-2014 Price: US $1295 Onwards Pages: 126
BMI View: Egypt's relative political stability will lead to a pickup in growth over the coming quarters,
increasing the attractiveness of the pharmaceutical market - for which our forecast has been revised slightly
upwards. The government's increased emphasis on developing the pharmaceutical sector and the
announced expansion of the Medicare healthcare programme are positive developments this quarter. The
challenges faced by pharmaceutical companies wishing to operate in the market are the c......
Global Pharmaceutical Packaging Market 2014-2018
Published: 29-Oct-2014 Price: US $2500 Onwards Pages: 77
A pharmaceutical product is any chemical substance formulated or compounded as a single active ingredient. The packaging of medicines is a very complex process, and because of its molecular and chemical structure, it needs to be packed in an extremely durable material so that it could reach the customer in a desirable condition. The evolution of new diseases and increased health awareness have brought a transformation in the Pharmaceutical Packaging market. The vendors in the Global Pharmaceutic......
Indonesia Pharmaceuticals and Healthcare Report Q4 2014
Published: 29-Oct-2014 Price: US $1295 Onwards Pages: 142
BMI View: Indonesia is one of the most promising markets for the pharmaceutical and healthcare
companies in South East Asia. The country's large population, positive economic outlook and considerable
disease burden bode well for growth in demand for drugs, medical devices and healthcare services. The
ongoing implementation of the universal healthcare scheme in Indonesia coupled with the impending
launch of the ASEAN Economic Community will provide growth opportunities for pharmaceutical firm......
Global Polymerase Chain Reaction (PCR) Market 2014-2018
Published: 29-Oct-2014 Price: US $2500 Onwards Pages: 75
Polymerase Chain Reaction (PCR) is a technique of molecular genetics, which allows amplification and analysis of nucleic acid. It is very precise, specific and accurate technique used to amplify a specific DNA target from a mixture of DNA molecules. It is used in a wide array of applications in research and diagnosis, including genetic engineering, cloning, sequencing, diagnosis, genotyping, and many other areas. Advances in PCR technology and tools provide high reproducibility within a short pe......
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details - [email protected]
/ +1 888 391 5441 )
- Ad Hoc
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs